Covid-19 roundup: WHO looks to boost pro­duc­tion of an­ti­body tests in low­er-in­come coun­tries; US gov­ern­ment fights to ...

4 years ago
Coronavirus

The lat­est threat to the man­u­fac­tur­ing in­dus­try: sus­pi­cious mal­ware

4 years ago
Manufacturing

FDA ap­proves pricey new treat­ment for ul­tra-rare and ag­gres­sive form of sar­co­ma

4 years ago
Pharma
FDA+

Did Eu­rope blun­der in its Covid vac­cine picks? Pas­cal So­ri­ot points to a po­ten­tial mis­take — and jabs back over ...

4 years ago
Coronavirus

A fledg­ling transpa­cif­ic biotech grabs a launch round to dive in­to on­col­o­gy and au­toim­mune re­search

4 years ago
Financing

Vac­ci­body gets a new name and loads up with near­ly $1B in biobucks for new vac­cine pact with Re­gen­eron

4 years ago
Deals

Eight years and $1.3B lat­er, As­traZeneca fi­nal­ly un­veils Cam­bridge R&D palace

4 years ago
Pharma

At busy Visp site, Lon­za will up mi­cro­bial ser­vices by 50%

4 years ago
Manufacturing

New drug ap­pli­ca­tions pile up with de­lays as there's no easy fix for the in­spec­tion back­log

4 years ago
Manufacturing

House com­mit­tee wants for­mer FDA com­mis­sion­er to come clean on Covid-re­lat­ed po­lit­i­cal in­ter­fer­ence

4 years ago
FDA+

Glax­o­SmithK­line places a risky bet on Ar­row­head­'s RNA drug in the fail­ure-strewn NASH field

4 years ago
Deals

Bio­gen pulls PRIME des­ig­na­tion for ad­u­canum­ab in Eu­rope; Mer­ck clos­es merg­er with Ac­celeron

4 years ago
News Briefing

Sanofi con­tin­ues mR­NA push in wake of Covid vac­cine set­back, part­ner­ing with Chi­na tech gi­ant Baidu

4 years ago
Deals
AI

NeuEx­cell heads east, land­ing sub­ur­ban Philly head­quar­ters

4 years ago
Cell/Gene Tx
Manufacturing

Af­fimed spurs promis­ing re­sponse num­bers in NK cell study, but dura­bil­i­ty will be the big ques­tion

4 years ago
R&D
Cell/Gene Tx

Rafael Hold­ings guts its top lead­er­ship, in­clud­ing short-tenured CEO, as can­cer fi­as­co spurs a shake­up

4 years ago
People

Blue­bird bio may fi­nal­ly get a gene ther­a­py ap­proved in the US

4 years ago
R&D
Cell/Gene Tx

BioCryst gets mas­sive cash in­fu­sion to the tune of $350M, thanks to old and new in­vestors

4 years ago
Financing

Bounc­ing back from a PhII flop in schiz­o­phre­nia, Neu­ro­crine steers in­to the busy M4/M1 path­way with a $100M cash deal

4 years ago
Deals
R&D

Glax­o­SmithK­line's Trel­e­gy ad change-up spurs bet­ter re­lata­bil­i­ty with COPD pa­tients — and more doc­tor con­ver­sa­tions

4 years ago
Pharma
Marketing

The an­ti­body dis­cov­ery team at Twist bets on mouse mod­el play­er in a boost to its port­fo­lio

4 years ago
Deals
Discovery

Xen­cor says good­bye to its for­mer lead drug, sell­ing all rights to Lon­nie Moul­der's new start­up

4 years ago
Deals

New Pfiz­er/BioN­Tech Covid vac­cine da­ta in teens show strong pro­tec­tion, lin­ing up sBLA fil­ing

4 years ago
FDA+
Coronavirus

Two of Chi­na's top PD-(L)1 play­ers team up on CT­LA-4 in $200M deal

4 years ago
Deals
China
First page Previous page 610611612613614615616 Next page Last page
A service from the Financial Times